Citi released a research report stating that it maintains a "Buy" rating for Hutchmed (China) (00013), raising the Target Price from HK$38.9 to HK$42. Furthermore, the bank lowered its revenue forecast for the company by 5% for this year and next year, taking into account the Trade of Shanghai and Hutchmed, adjusting the earnings per share forecast for the same period to $0.69 and $0.01 respectively.
花旗：维持和黄医药“买入”评级 目标价上调至42港元
Citi: Maintains Buy rating on Hutchmed (China), Target Price raised to HKD 42.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated